AR062319A1 - Derivados de 2-(heterociclilbencil)-piridazinona, un procedimiento para su preparacion, su uso en la fabricacion de un medicamento para el tratamiento de enfermedades afectadas por la inhibicion de la met-quinasa y un kit para su utilizacion. - Google Patents
Derivados de 2-(heterociclilbencil)-piridazinona, un procedimiento para su preparacion, su uso en la fabricacion de un medicamento para el tratamiento de enfermedades afectadas por la inhibicion de la met-quinasa y un kit para su utilizacion.Info
- Publication number
- AR062319A1 AR062319A1 ARP070103543A ARP070103543A AR062319A1 AR 062319 A1 AR062319 A1 AR 062319A1 AR P070103543 A ARP070103543 A AR P070103543A AR P070103543 A ARP070103543 A AR P070103543A AR 062319 A1 AR062319 A1 AR 062319A1
- Authority
- AR
- Argentina
- Prior art keywords
- nhet1
- derivative
- het1
- nhconh
- hal
- Prior art date
Links
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 150000004866 oxadiazoles Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- MZAGXDHQGXUDDX-JSRXJHBZSA-N (e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/C(N)=O MZAGXDHQGXUDDX-JSRXJHBZSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 230000001351 cycling effect Effects 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical class C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000002152 alkylating effect Effects 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 abstract 1
- 150000001540 azides Chemical class 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 150000007978 oxazole derivatives Chemical class 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- -1 pyrrolidino, piperidino Chemical group 0.000 abstract 1
- 230000003381 solubilizing effect Effects 0.000 abstract 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos de la formula (1) en donde R1 es Ar o Het, R2 es un heterociclo de 5 miembros saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono- o disustituido con Hal, A, (CH2)nOR3, N(R3)2, SR3, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3SO2A, SO2N(R3)2, S(O)mA, Het1, -[C(R3)2]nN(R3)2, -[C(R3)2]nHet1, O[C(R3)2]nN(R3)2, O[C(R3)2]nHet1, S[C(R3)2]nN(R3)2, S[C(R3)2]nHet1, -NR3[C(R3)2]nN(R3)2, -NR3[C(R3)2]nHet1, -NR3Het1, NHCON(R3)2, NHCONH[C(R3)2]nN(R3)2, NHCONH[C(R3)2]nHet1, CON(R3)2, ONR3[C(R3)2]nN(R3)2, CONR3[C(R3)2]nHet1, COHet1, COA y/u =O (oxígeno del carbonilo), R4, R5 es en cada caso, de modo independiente entre sí, H, Hal, A, OR3, CN, COOR3, CON(R3)2, NR3COA, NR3SO2A, SO2N(R3)2 o S(O)mA; A es alquilo no ramificado o ramificado con 1-10 átomos de C, donde 1-7 átomos de H pueden estar reemplazados por F, Cl y/o Br, y/o en donde uno o dos grupos CH2 pueden estar reemplazados por O, S, SO, SO2, y/o grupos CH=CH, o alquilo cíclico con 3-7 átomos de C; Ar es fenilo, naftilo o bifenilo no sustituido o mono-, di- o trisustituido con Hal, A, OR3, N(R3)2, SR3, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3SO2A, SO2N(R3)2, S(O)mA, CO-Het1, Het1, O[C(R3)2]nN(R3)2, O[C(R3)2]nHet1, NHCOOA, NHCON(R3)2, NHCOO[C(R3)2]nN(R3)2, NHCOO[C(R3)2]nHet1, NHCONH[C(R3)2]nN(R3)2, NHCONH[C(R3)2]nHet1, OCONH[C(R3)2]nN(R3)2, OCONH[C(R3)2]nHet1 y/o COA; Het es un heterociclo mono-, di- o tricíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con Hal, A, OR3, N(R3)2, SR3, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3SO2A, SO2N(R3)2, S(O)mA, CO-Het1, Het1, O[C(R3)2]nN(R3)2, O[C(R3)2]nHet1, NHCOOA, NHCON(R3)2, NHCOO[C(R3)2]nN(R3)2, NHCOO[C(R3)2]nHet1, NHCONH[C(R3)2]nN(R3)2, NHCONH[C(R3)2]nHet1, OCONH[C(R3)2]nN(R3)2, OCONH[C(R3)2]nHet1, CO-Het1, CHO, COA, =S, =NH, =NA y/u =O (oxígeno del carbonilo), Het1 es un heterociclo monocíclico saturado o aromático con 1 a 2 átomos de N y/u O, que puede estar mono- o disustituido con A, OA, OH, Hal, (CH2)nN(R3)2, (CH2)nOR3, (CH2)nHet2 y/u =O (oxígeno del carbonilo), Het2 es pirrolidino, piperidino o morfolino, Hal es F, Cl, Br o I, m es 0, 1, o 2, n es 1, 2, 3, o 4, así como sus derivados, solvatos, sales, tautomeros y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones. Son inhibidores de las tirosina quinasas, en especial de la Met-quinasa, y pueden utilizarse, por ejemplo, para preparar medicamentos para el tratamiento de tumores. Reivindicacion 16: Procedimiento para preparar compuestos de la formula 1 de acuerdo con las reivindicaciones 1-15, así como sus derivados, sales, solvatos, tautomeros y estereoisomeros de utilidad farmacéutica, caracterizado porque se hace reaccionar a) un compuesto de la formula (2) en donde R1 tiene el significado indicado en la reivindicacion 1, con un compuesto de la formula (3) en donde R2, R3, R4 y R5 tienen el significado indicado en la reivindicacion 1 y L es Cl, Br, I o un grupo OH libre o transformado reactivamente de manera funcional, o b) un radical R2 se convierte en otro radical R2, i) acilando o alquilando un grupo amino, ii) ciclando un derivado de oxi-amidina en un derivado de oxadiazol, iii) ciclando un derivado de amida en un derivado de oxazol, iv) haciendo reaccionar un derivado de éster alquílico con un derivado de N-hidroxiamidina en un derivado de oxadiazol, v) ciclando un derivado de N-(aminotiocarbonil)hidrazida en un derivado de oxadiazol, vi) alquilando un grupo SH, vii) haciendo reaccionar un grupo ciano con un derivado de azida en un derivado de tetrazol o c) porque se los libera de uno de sus derivados funcionales por tratamiento con un agente solvolizante o hidrogenolizante, y/o se convierte una base o ácido de la formula 1 en una de sus sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006037478A DE102006037478A1 (de) | 2006-08-10 | 2006-08-10 | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062319A1 true AR062319A1 (es) | 2008-10-29 |
Family
ID=38917674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103543A AR062319A1 (es) | 2006-08-10 | 2007-08-10 | Derivados de 2-(heterociclilbencil)-piridazinona, un procedimiento para su preparacion, su uso en la fabricacion de un medicamento para el tratamiento de enfermedades afectadas por la inhibicion de la met-quinasa y un kit para su utilizacion. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8435981B2 (es) |
| EP (1) | EP2049531B1 (es) |
| JP (1) | JP5290972B2 (es) |
| KR (1) | KR20090039836A (es) |
| CN (1) | CN101501028B (es) |
| AR (1) | AR062319A1 (es) |
| AU (1) | AU2007283184B2 (es) |
| BR (1) | BRPI0716502A2 (es) |
| CA (1) | CA2660195C (es) |
| DE (1) | DE102006037478A1 (es) |
| ES (1) | ES2525120T3 (es) |
| IL (1) | IL196876A0 (es) |
| MX (1) | MX2009001427A (es) |
| WO (1) | WO2008017361A2 (es) |
| ZA (1) | ZA200901668B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6866901B2 (en) | 1999-10-25 | 2005-03-15 | Vitex Systems, Inc. | Method for edge sealing barrier films |
| US20100330748A1 (en) | 1999-10-25 | 2010-12-30 | Xi Chu | Method of encapsulating an environmentally sensitive device |
| US8808457B2 (en) | 2002-04-15 | 2014-08-19 | Samsung Display Co., Ltd. | Apparatus for depositing a multilayer coating on discrete sheets |
| MX2009000884A (es) | 2006-07-25 | 2009-06-05 | Cephalon Inc | Derivados de piridizinona. |
| DE102006037478A1 (de) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
| JP5278318B2 (ja) | 2006-12-14 | 2013-09-04 | アステラス製薬株式会社 | Ｃｒｔｈ２拮抗剤および抗アレルギー剤として有用な多環酸化合物 |
| MX2009008531A (es) | 2007-02-16 | 2009-08-26 | Amgen Inc | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. |
| DE102007025718A1 (de) * | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007025717A1 (de) | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
| DE102007041115A1 (de) * | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | Thiadiazinonderivate |
| DE102007061963A1 (de) * | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102008019907A1 (de) * | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
| US9184410B2 (en) | 2008-12-22 | 2015-11-10 | Samsung Display Co., Ltd. | Encapsulated white OLEDs having enhanced optical output |
| US9337446B2 (en) | 2008-12-22 | 2016-05-10 | Samsung Display Co., Ltd. | Encapsulated RGB OLEDs having enhanced optical output |
| DE102008062826A1 (de) * | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102009003954A1 (de) * | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102009004061A1 (de) * | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | Pyridazinonderivate |
| US8590338B2 (en) | 2009-12-31 | 2013-11-26 | Samsung Mobile Display Co., Ltd. | Evaporator with internal restriction |
| JP2013517281A (ja) * | 2010-01-13 | 2013-05-16 | テンペロ、ファーマシューティカルズ、インコーポレイテッド | 化合物及び方法 |
| WO2012003338A1 (en) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| CN102731409A (zh) * | 2011-04-08 | 2012-10-17 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物，其药物组合物、制备方法及用途 |
| PT2953944T (pt) * | 2013-02-07 | 2017-08-01 | Merck Patent Gmbh | Derivados de piridazinona-amidas |
| US10398774B2 (en) | 2014-12-09 | 2019-09-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against AXL |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| US11365193B2 (en) | 2017-07-27 | 2022-06-21 | Nippon Soda Co., Ltd. | Oxadiazole compound and fungicide for agricultural and horticultural use |
| EP3778583B1 (en) | 2018-03-30 | 2025-06-18 | Sumitomo Chemical Company, Limited | Heterocyclic compound and arthropod pest control composition containing same |
| CN113662938B (zh) * | 2021-09-26 | 2022-08-16 | 广西科技大学 | 一种胺类衍生物在制备抗肿瘤药物组合物中的应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5795964A (en) | 1980-12-04 | 1982-06-15 | Morishita Seiyaku Kk | Preparation of 2-substituted-3(2h)-pyridazinone derivative |
| US4397854A (en) | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| IL115889A0 (en) | 1994-11-14 | 1996-01-31 | Rohm & Haas | Pyridazinones and their use as fungicides |
| US5635494A (en) | 1995-04-21 | 1997-06-03 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| AU719434B2 (en) | 1996-02-13 | 2000-05-11 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
| ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| PT1005460E (pt) * | 1997-08-22 | 2006-07-31 | Abbott Lab | Biossintese de inibidores de prostaglandina-endoperoxido h-sintase |
| HUP0100059A3 (en) | 1997-11-19 | 2002-08-28 | Kowa Co | Novel pyridazine derivatives and drugs containing the same as the active ingredient |
| JP3335132B2 (ja) * | 1997-11-19 | 2002-10-15 | 興和株式会社 | 新規ピリダジン誘導体及びこれを有効成分とする医薬 |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
| CA2411160A1 (en) | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| CA2462525A1 (en) | 2001-10-31 | 2003-05-08 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Type 4 phosphodiesterase inhibitors and uses thereof |
| JP2005519895A (ja) * | 2002-01-18 | 2005-07-07 | ファルマシア・コーポレーション | Ｐ３８阻害剤としての置換ピリダジノン |
| US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
| DE10349587A1 (de) | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
| EP1755871B1 (en) | 2004-06-04 | 2012-01-04 | Cornerstone Research Group, Inc. | Method of using shape memory polymer composite patches |
| CA2573764A1 (en) | 2004-07-16 | 2006-02-23 | Schering Corporation | Hydantoin derivatives for the treatment of inflammatory disorders |
| AU2006264212B2 (en) | 2005-06-29 | 2010-10-28 | Compumedics Limited | Sensor assembly with conductive bridge |
| DE102005057924A1 (de) | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102006037478A1 (de) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
| WO2010113986A1 (ja) * | 2009-03-30 | 2010-10-07 | 住友化学株式会社 | ピリダジノン化合物の有害節足動物防除用途 |
-
2006
- 2006-08-10 DE DE102006037478A patent/DE102006037478A1/de not_active Withdrawn
-
2007
- 2007-07-12 EP EP07786018.7A patent/EP2049531B1/de not_active Not-in-force
- 2007-07-12 ES ES07786018.7T patent/ES2525120T3/es active Active
- 2007-07-12 BR BRPI0716502-1A patent/BRPI0716502A2/pt not_active IP Right Cessation
- 2007-07-12 CN CN2007800298127A patent/CN101501028B/zh not_active Expired - Fee Related
- 2007-07-12 KR KR1020097004915A patent/KR20090039836A/ko not_active Ceased
- 2007-07-12 MX MX2009001427A patent/MX2009001427A/es active IP Right Grant
- 2007-07-12 WO PCT/EP2007/006186 patent/WO2008017361A2/de not_active Ceased
- 2007-07-12 AU AU2007283184A patent/AU2007283184B2/en not_active Ceased
- 2007-07-12 CA CA2660195A patent/CA2660195C/en not_active Expired - Fee Related
- 2007-07-12 US US12/377,072 patent/US8435981B2/en not_active Expired - Fee Related
- 2007-07-12 JP JP2009523165A patent/JP5290972B2/ja not_active Expired - Fee Related
- 2007-08-10 AR ARP070103543A patent/AR062319A1/es not_active Application Discontinuation
-
2009
- 2009-02-03 IL IL196876A patent/IL196876A0/en not_active IP Right Cessation
- 2009-03-09 ZA ZA200901668A patent/ZA200901668B/xx unknown
-
2013
- 2013-01-11 US US13/739,484 patent/US9221806B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0716502A2 (pt) | 2013-04-02 |
| KR20090039836A (ko) | 2009-04-22 |
| CN101501028B (zh) | 2013-09-11 |
| US20130131037A1 (en) | 2013-05-23 |
| ES2525120T3 (es) | 2014-12-17 |
| JP5290972B2 (ja) | 2013-09-18 |
| CA2660195C (en) | 2014-10-21 |
| WO2008017361A3 (de) | 2008-06-12 |
| DE102006037478A1 (de) | 2008-02-14 |
| CN101501028A (zh) | 2009-08-05 |
| ZA200901668B (en) | 2009-12-30 |
| EP2049531B1 (de) | 2014-09-24 |
| AU2007283184B2 (en) | 2012-08-23 |
| US8435981B2 (en) | 2013-05-07 |
| CA2660195A1 (en) | 2008-02-14 |
| AU2007283184A1 (en) | 2008-02-14 |
| JP2010500297A (ja) | 2010-01-07 |
| MX2009001427A (es) | 2009-02-17 |
| IL196876A0 (en) | 2009-11-18 |
| US20100261697A1 (en) | 2010-10-14 |
| WO2008017361A2 (de) | 2008-02-14 |
| US9221806B2 (en) | 2015-12-29 |
| EP2049531A2 (de) | 2009-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062319A1 (es) | Derivados de 2-(heterociclilbencil)-piridazinona, un procedimiento para su preparacion, su uso en la fabricacion de un medicamento para el tratamiento de enfermedades afectadas por la inhibicion de la met-quinasa y un kit para su utilizacion. | |
| AR066543A1 (es) | Derivados de piridazinona | |
| AR066770A1 (es) | Derivados de piridazinona | |
| AR057214A1 (es) | Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas. | |
| PE20230820A1 (es) | Derivados de biarilo como inhibidores de la interaccion proteina-proteina de yap/taz-tead | |
| ES2533954T3 (es) | Derivados de resorcinol como inhibidores de HSP90 | |
| AR072792A1 (es) | DERIVADOS DE PIRROLOPIRIDINILPIRIMIDIN-2-IL-AMINA, PROCEDIMIENTO DE PREPARACIoN Y COMPOSICIONES FARMACEUTICAS | |
| BR122012009489B8 (pt) | processo para produzir 2-etóxi-1-{[2-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso | |
| AR069843A1 (es) | Derivados de piridazinona, procedimiento para preparar dichos compuestos, composiciones farmaceuticas y usos de los mismos para preparar un medicamento | |
| AR076006A1 (es) | Compuestos heterociclicos inhibidores de autotaxina utiles para el tratamiento de tumores, proceso para prepararlos y medicamentos que los contienen. | |
| AR071208A1 (es) | Derivados de piridazinona | |
| RU2008109908A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| AR047329A1 (es) | Derivados de quinolinas para el tratamiento de enfermedades cardiovasculares. composiciones farmaceuticas | |
| AR035548A1 (es) | Compuestos organicos | |
| AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina | |
| RU2011116160A (ru) | Производные пиридина, замещенные гетероциклическим кольцом и y-глутамиламиногруппой и содержащие их противогрибковые средства | |
| AR063707A1 (es) | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden. | |
| AR063706A1 (es) | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. | |
| RU2009143926A (ru) | Производные пиридина, замещенные гетероциклическим циклом и фосфоноаминогруппой, и содержащее их противогрибковое средство | |
| ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
| AR063946A1 (es) | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. | |
| EA200700141A1 (ru) | Новые аминоциклические производные мочевины, их получение и фармацевтическое применение в качестве ингибиторов киназы | |
| AR066769A1 (es) | Derivados de arileter-piridazinona | |
| ES2545352T3 (es) | Derivados de la furopiridina | |
| EA012607B1 (ru) | НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |